Advertisement

Enhanced RFS With ERBT Over cTURBT in NMIBC

June, 06, 2024 | Bladder Cancer, Genitourinary Cancer

KEY TAKEAWAYS

  • The study aimed to investigate the comparative efficacy and perioperative outcomes of ERBT vs cTURBT in the treatment of patients with NMIBC.
  • Researchers noticed ERBT yielded better or comparable outcomes and improved RFS.

En-Bloc transurethral resection of bladder tumor (ERBT) was clinically used to resect non-muscle-invasive bladder cancer (NMIBC). However, discrepancies persist regarding the comparisons between ERBT and conventional transurethral resection of bladder tumor (cTURBT).

Deng-Xiong Li and the team aimed to assess the overall effectiveness and benefits of ERBT compared to cTURBT in treating NMIBC.

They performed an inclusive analysis by conducting a comprehensive search in PubMed, Embase, Web of Science, Cochrane Database of Systematic Reviews, and manual searches of reference lists to collect and extract data. Data evaluation was carried out using Review Manager 5.4.0, Rx64 4.1.3, and relevant packages.

About 9 eligible meta-analyses and 9 eligible RCTs were included in the study. Patients with NMIBC undergoing ERBT were significantly associated with a lower rate of bladder perforation and obturator nerve reflex compared to those receiving cTURBT. The pooled results indicated that ERBT and cTURBT required similar operation time. Regarding postoperative outcomes, ERBT demonstrated superior performance compared to cTURBT in terms of detrusor muscle presence, catheterization time, and residual tumor.

ERBT exhibited a higher rate of 3-month recurrence-free survival (RFS) compared to those receiving cTURBT (P < 0.05; I2 = 0%). In the bipolar subgroup, ERBT had a significantly better 12-month RFS than cTURBT (P < 0.05; I2 = 0%). Simultaneously, the exclusion of Hybrid Knife data revealed a significant improvement in 12-month RFS associated with ERBT (P < 0.05; I2 = 50%).

The study concluded that, using a combination of umbrella review and meta-analysis, ERBT had better or comparable perioperative outcomes and improved 3 and 12-month RFS compared to cTURBT. ERBT may be a better surgical method for patients with NMIBC.

This study was funded by the Chinese Scholarship Council.

Source: https://pubmed.ncbi.nlm.nih.gov/38819629/

Li DX, Yu QX, Wu RC, et al. (2024). “Efficiency of transurethral en-bloc resection vs. conventional transurethral resection for non-muscle-invasive bladder cancer: An umbrella review.” Cancer Med. 2024 Jun;13(11):e7323. doi: 10.1002/cam4.7323. PMID: 38819629; PMCID: PMC11141332.

For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –

Advertisement

LATEST

Advertisement

Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy